Age-related skeletal muscle decline is similar in HIV-infected and uninfected individuals.

Department of Medicine, Washington University, St. Louis, Missouri, USA.
The Journals of Gerontology Series A Biological Sciences and Medical Sciences (Impact Factor: 4.31). 03/2011; 66(3):332-40. DOI: 10.1093/gerona/glq228
Source: PubMed

ABSTRACT Skeletal muscle (SM) mass decreases with advanced age and with disease in HIV infection. It is unknown whether age-related muscle loss is accelerated in the current era of antiretroviral therapy and which factors might contribute to muscle loss among HIV-infected adults. We hypothesized that muscle mass would be lower and decline faster in HIV-infected adults than in similar-aged controls.
Whole-body (1)H-magnetic resonance imaging was used to quantify regional and total SM in 399 HIV-infected and 204 control men and women at baseline and 5 years later. Multivariable regression identified associated factors.
At baseline and Year 5, total SM was lower in HIV-infected than control men. HIV-infected women were similar to control women at both time points. After adjusting for demographics, lifestyle factors, and total adipose tissue, HIV infection was associated with lower Year 5 SM in men and higher SM in women compared with controls. Average overall 5-year change in total SM was small and age related, but rate of change was similar in HIV-infected and control men and women. CD4 count and efavirenz use in HIV-infected participants were associated with increasing SM, whereas age and stavudine use were associated with decreasing SM.
Muscle mass was lower in HIV-infected men compared with controls, whereas HIV-infected women had slightly higher SM than control women after multivariable adjustment. We found evidence against substantially faster SM decline in HIV infected versus similar-aged controls. SM gain was associated with increasing CD4 count, whereas stavudine use may contribute to SM loss.

1 Bookmark
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Motor impairment is highly prevalent in HIV-infected patients. Here, we assess associations between peripheral muscular deficits as evaluated by the 5 sit-to-stand test (5STS) and structural integrity of the motor system at a central level. Eighty-six HIV-infected patients receiving combination antiretroviral therapy and with no major cerebral events, underwent an MRI scan and the 5STS. Out of 86 participants, forty presented a score greater than two standard deviations above mean normative scores calculated for the 5STS and were therefore considered as motor-impaired. MRI-structural cerebral parameters were compared to the unimpaired participants. Fractional Anisotropy (FA), Axial Diffusivity (AD) and Radial Diffusivity (RD), reflecting microstructural integrity, were extracted from Diffusion-Tensor MRI. Global and regional cerebral volumes or thicknesses were extracted from 3D-T1 morphological MRI. Whereas the two groups did not differ for any HIV variables, voxel-wise analysis revealed that motor-impaired participants present low FA values in various cortico-motor tracts and low AD in left cortico-spinal tract. However, they did not present reduced volumes or thicknesses of the precentral cortices compared to unimpaired participants. The absence of alterations in cortical regions holding motor-neurons might argue against neurodegenerative process as an explanation of White Matter (WM) disorganization.
    PLoS ONE 07/2013; 8(7):66810-. DOI:10.1371/journal.pone.0066810 · 3.53 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: In HIV-infected persons, osteoporosis is common and has a multifactorial etiology including traditional risk factors, such as smoking and low body weight, as well as direct effects of HIV infection and antiretroviral therapy. Multiple studies indicate that HIV-infected persons are at increased risk of low bone mass as compared to the general population. Emerging data suggest that the increased prevalence of reduced bone mass in HIV infection predisposes patients to an increased risk of fracture. This review discusses the epidemiology of low bone mass and fracture in HIV-infected persons, addresses the multiple causes of reduced bone mineral density in HIV infection, and offers recommendations on screening HIV-infected persons for bone loss.
    Clinical Reviews in Bone and Mineral Metabolism 12/2012; 10(4). DOI:10.1007/s12018-012-9132-z
  • [Show abstract] [Hide abstract]
    ABSTRACT: To compare the effect that initiating different antiretroviral therapy (ART) regimens has on weight, BMI, and lean body mass (LBM) and explore how changes in body composition are associated with bone mineral density (BMD). A5224s was a sub-study of A5202, a prospective trial of 1857 ART-naive participants randomized to blinded abacavir-lamivudine (ABC/3TC) or tenofovir DF-emtricitabine (TDF/FTC) with open-label efavirenz (EFV) or atazanavir-ritonavir (ATV/r). All participants underwent dual-energy absorptiometry (DXA) and abdominal computed tomography for body composition. Analyses used two-sample t-tests and linear regression. A5224s included 269 participants: 85% men, 47% white non-Hispanic, median age 38 years, HIV-1 RNA 4.6 log10 copies/ml, and CD4 cell count 233 cells/μl. Overall, significant gains occurred in weight, BMI, and LBM at 96 weeks postrandomization (all P < 0.001). Assignment to ATV/r (vs. EFV) resulted in significantly greater weight (mean difference 3.35 kg) and BMI gain (0.88 kg/m; both P = 0.02), but not LBM (0.67 kg; P = 0.15), whereas ABC/3TC and TDF/FTC were not significantly different (P ≥ 0.10). In multivariable analysis, only lower baseline CD4 cell count and higher HIV-1 RNA were associated with greater increase in weight, BMI, or LBM. In multivariable analyses, increased LBM was associated with an increased hip BMD. ABC/3TC vs. TDF/FTC did not differ in change in weight, BMI, or LBM; ATV/r vs. EFV resulted in greater weight and BMI gain but not LBM. A positive association between increased LBM and increased hip BMD should be further investigated through prospective interventional studies to verify the impact of increased LBM on hip BMD.
    AIDS (London, England) 08/2013; 27(13):2069-79. DOI:10.1097/QAD.0b013e328361d25d · 6.56 Impact Factor

Full-text (2 Sources)

Available from
May 31, 2014